Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Orlowski RZ, et al. Among authors: ivanova a. Blood. 2005 Apr 15;105(8):3058-65. doi: 10.1182/blood-2004-07-2911. Epub 2004 Dec 30. Blood. 2005. PMID: 15626743 Free article. Clinical Trial.
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Dees EC. Stinchcombe TE, et al. Among authors: ivanova a. Cancer Chemother Pharmacol. 2007 Oct;60(5):759-66. doi: 10.1007/s00280-007-0423-x. Epub 2007 Feb 7. Cancer Chemother Pharmacol. 2007. PMID: 17285317 Free PMC article. Clinical Trial.
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ. Dees EC, et al. Among authors: ivanova a. Cancer Chemother Pharmacol. 2008 Dec;63(1):99-107. doi: 10.1007/s00280-008-0716-8. Epub 2008 Mar 8. Cancer Chemother Pharmacol. 2008. PMID: 18327587 Free PMC article. Clinical Trial.
Phase I trial of vinflunine and pemetrexed in refractory solid tumors.
Sanoff HK, Davies J, Walko C, Buie L, Chiu WK, Ivanova A, O'Neil B, Stinchcombe TE, Keller K, Dees EC. Sanoff HK, et al. Among authors: ivanova a. Invest New Drugs. 2011 Feb;29(1):131-6. doi: 10.1007/s10637-009-9344-3. Epub 2009 Oct 15. Invest New Drugs. 2011. PMID: 19830387 Free PMC article. Clinical Trial.
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Davies JM, Dhruva NS, Walko CM, Socinski MA, Bernard S, Hayes DN, Kim WY, Ivanova A, Keller K, Hilbun LR, Chiu M, Dees EC, Stinchcombe TE. Davies JM, et al. Among authors: ivanova a. Lung Cancer. 2011 Feb;71(2):151-5. doi: 10.1016/j.lungcan.2010.05.022. Epub 2010 Jul 1. Lung Cancer. 2011. PMID: 20580118 Free PMC article. Clinical Trial.
A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Foster MC, Amin C, Voorhees PM, van Deventer HW, Richards KL, Ivanova A, Whitman J, Chiu WM, Barr ND, Shea T. Foster MC, et al. Among authors: ivanova a. Leuk Lymphoma. 2012 Jul;53(7):1331-7. doi: 10.3109/10428194.2011.647313. Epub 2012 Jan 31. Leuk Lymphoma. 2012. PMID: 22149206 Clinical Trial.
1,188 results